Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).

9075Background: Hyperprogressive disease (HPD) emerges as a new subset of patients treated with immune-oncology (IO) agent. The definition of HPD is not yet clearly established, and it is unclear w...